Pinealon vs Semax
A side-by-side research comparison of Pinealon and Semax across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Pinealon | Semax |
|---|---|---|
| Full name | Pinealon (Glu-Asp-Arg) | Semax (ACTH 4-10 analog) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | As a peptide bioregulator it is proposed to penetrate cells and interact with DNA to modulate gene expression in neural tissue, reducing oxidative damage and supporting neuronal survival and protein synthesis. | Activates MC3/4R, increases BDNF and NGF, modulates dopamine/serotonin, enhances neuronal survival via TrkB, and promotes CREB-mediated neuroplasticity. |
| Molecular weight | ~418 Da | 813.9 Da |
| Half-life | Short (small peptide, rapidly metabolized) | 3-5 min (systemic) / extended (intranasal) |
| Bioavailability | Injectable in research; intranasal also used | Moderate (intranasal) |
| Typical dose | ~5-10 mg per course day (research) | 200-600 mcg per dose |
| Frequency | Daily during a short course | 2-3x daily |
| Route | Subcutaneous or intranasal | Intranasal drops/spray |
Pinealon reported benefits
- Neuroprotective and antioxidant effects (research)
- Supports cognition under stress/aging
- May support healthy sleep-wake regulation
- Short-course bioregulator profile
Semax reported benefits
- Enhanced attention/focus
- Memory improvement
- Neuroprotection (stroke)
- BDNF/NGF upregulation
- Improved learning
- Optic nerve support
Related comparisons
Research and educational reference only. Not medical advice.